Reveal Pharmaceuticals

Reveal Pharmaceuticals is pioneering the development of gadolinium-free MRI contrast agents and first-in-class fibrogenesis imaging agents. Its lead candidate, RVP-001, is a manganese-based agent in Phase 2 clinical studies with FDA Fast Track designation, targeting the 65-million-dose-per-year global MRI contrast market. The company is led by an experienced team with deep expertise in radiology and contrast agent development and is backed by over $17M in NIH and other grants. Reveal aims to displace current gadolinium-based agents by offering a safer alternative for patients and reducing environmental pollution and supply chain vulnerabilities.

Platform for developing novel metal-based MRI contrast agents, primarily using biocompatible manganese to replace toxic gadolinium, and targeted molecular probes for imaging active fibrogenesis.

Reveal competes against dominant, generic gadolinium-based contrast agents (GBCAs) from companies like Bayer, GE Healthcare, and Bracco. Its primary differentiation is safety and sustainability. It also faces emerging competition from other groups developing non-gadolinium agents (e.g., iron oxide or alternative manganese compounds). In fibrosis imaging, it is a first-in-class pioneer, but large imaging and pharma companies may enter if the market validates.